Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active myeloma, according to findings from the phase III AQUILA trial presented at the ...
Darzalex Faspro improved PFS and OS in high-risk smoldering multiple myeloma, reducing progression or death risk by 51% and death risk by 48%. The AQUILA study showed a superior overall response rate ...
SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...
Darzalex Faspro reduced the risk of disease progression to active multiple myeloma or death by 51% compared with active monitoring. The Food and Drug Administration (FDA) has approved Darzalex Faspro ...
Darzalex Faspro's FDA application targets high-risk smoldering multiple myeloma, a precursor to active multiple myeloma with no current approved treatments. The phase 3 AQUILA study supports the ...
Phase 3 AQUILA study showed DARZALEX FASPRO ® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports ...
Please provide your email address to receive an email when new articles are posted on . Daratumumab delayed progression of smoldering multiple myeloma compared with active monitoring. Among those who ...
Saad Z. Usmani, MD, MBA, FACP, discusses how the AQUILA study data presented at ASH 2024, highlighting the benefits of early intervention in high-risk smoldering multiple myeloma, could impact ...
First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study ...
The multicenter, international AQUILA study randomly assigned 390 patients with high-risk SMM to receive either daratumumab or active monitoring. After a median follow-up of 65.2 months, the study ...
The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer. Darzalex Faspro is the ...
A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. This story was originally published on BioPharma Dive. To receive daily news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results